Dendritic Cell Vaccine for Children and Adults With Sarcoma

M

Macarena De La Fuente, MD

Status and phase

Active, not recruiting
Phase 1

Conditions

Sarcoma
Soft Tissue Sarcoma
Bone Sarcoma

Treatments

Drug: Gemcitabine
Procedure: Leukapheresis
Biological: Lysate of Tumor
Drug: Imiquimod
Biological: Dendritic Cells Vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT01803152
20110462

Details and patient eligibility

About

The purpose if this study is to evaluate an investigational vaccine using patient-derived dendritic cells (DC), a type of white blood cell that helps fight infections in the body, (DC) (a vaccine made out of participants' own cells and tumor) to treat sarcoma.

Enrollment

19 patients

Sex

All

Ages

1 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age: 1 - 100 years old.

  2. Histologically or cytologically confirmed sarcoma either relapsed or without known curative therapies. Both bone sarcomas and soft tissue sarcomas are eligible. Osteosarcoma, chondrosarcoma, Ewing's sarcoma and any other diagnoses of sarcoma are eligible as long as there is soft tissue that can be excised and be used to prepare lysate. Subjects presenting only with lesions that are only comprised of bone are excluded. Any number of prior therapies is allowed, including zero.

  3. No radiotherapy to other sites planned and/or other chemotherapy planned for the study period. No radiotherapy or chemotherapy to have been received for at least 4 weeks before first vaccine administration. To allow for better local control without introducing undue toxicity into the trial, brachytherapy at time of surgery scheduled to end by one week before first vaccination is allowed if the radioactive source is to be removed (e.g. catheters can be placed if removable but implanted seeds are not allowed). In the event of positive margins being determined after surgical resection, but not determined in time for the placement of brachytherapy catheters, external beam radiotherapy may start after the last DC vaccination is administered but before the lysate boosts begin, and radiation must be planned to be complete before the first lysate boost.

  4. No treatment with corticosteroids, antihistamines or salicylates for at least 1 week before first vaccination.

  5. Adequate organ function (to be measured at enrollment)

    • Absolute neutrophil count (ANC) ≥ 0.75* 10^3/µL
    • Lymphocytes ≥ 0.5 * 10^3/µL
    • Platelets ≥ 75 * 10^3/µL
    • Hemoglobin ≥ 9 g/dL
    • Aspartate aminotransferase (AST)/Alanine transaminase (ALT) ≤ 2.5 X upper limit of normal (ULN); if liver metastases, ≤ 5 X ULN
    • Serum Creatinine ≤ 1.5 X ULN
    • Total Bilirubin ≤ 3 X ULN
    • Albumin > 2 g/dL
  6. Karnofsky/Lansky score of ≥ 70% or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

  7. Subjects must agree to use adequate method of contraception or abstinence throughout and up to 4 weeks after the study treatment completion.

  8. Life expectancy of > 3 months.

  9. Written consent by patient or parent(s) (if patient is < 18 years) on an institutional review board (IRB)-approved informed consent form prior to any study-specific evaluation. Assent is required from children as per University of Miami (UM) IRB guidelines. Subject must be capable of understanding the investigational nature, potential risks and benefits of the study and able to provide valid informed consent.

Exclusion criteria

  1. Pregnancy

  2. Breast feeding females.

  3. Any concomitant participation in other therapeutic trials

  4. Virus serology known to be positive for HIV (testing is not required in the absence of clinical suspicion)

  5. Documented immunodeficiency or autoimmune disease

  6. Concomitant treatment with corticosteroids, antihistamines (H1 and H2 inhibitors) or salicylates. Patients may be eligible if the treatment is stopped at least 1 week before the first vaccination.

  7. Brain metastases unless they have been stable for 3 months off of treatment directed specifically at them.

  8. Known allergy to gemcitabine or its formulation components. Intolerant to gemcitabine

    • Does not apply to cohorts to be treated without gemcitabine
    • Prior therapy with gemcitabine is allowed on all cohorts
  9. Refusal to use adequate contraception for fertile patients (females and males) during the study and for 30 days after the last dose of study treatment.

  10. Any serious or uncontrolled medical or psychiatric condition that in the opinion of the investigator makes the patient not able to participate in the study.

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

19 participants in 2 patient groups

Part 1-DC Vaccine/Lysate
Experimental group
Description:
Leukapheresis: Baseline, post-surgery; Dendritic Cells Vaccine (DC Vaccine): Post-Leukapheresis, administered once weekly in dose-escalation scheme for 4 weeks; Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 8, 12, 16 and 20; Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations.
Treatment:
Biological: Dendritic Cells Vaccine
Drug: Imiquimod
Biological: Lysate of Tumor
Procedure: Leukapheresis
Part 2-Gemcitabine/DC Vaccine/Lysate
Active Comparator group
Description:
Leukapheresis: Baseline, post-surgery; Gemcitabine: Post-Leukapheresis, administered once weekly for 3 weeks; Dendritic Cells Vaccine (DC Vaccine): Post-Gemcitabine therapy, Recommended Phase 2 Dose (RP2D) administered once weekly for 4 weeks; Lysate of Tumor (Lysate): Post-DC Vaccine therapy, administered during weeks 12, 16, 20 and 32; Imiquimod: Self-applied topically by subject before and after scheduled DC Vaccine or Lysate administrations.
Treatment:
Biological: Dendritic Cells Vaccine
Drug: Imiquimod
Biological: Lysate of Tumor
Procedure: Leukapheresis
Drug: Gemcitabine

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems